Get the Stockscreener App
456.04
1.44%
6.48
After Hours:
456.04
Alnylam Pharmaceuticals Inc stock is traded at $456.04, with a volume of 1.82M.
It is up +1.44% in the last 24 hours and up +0.01% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$449.56
Open:
$449
24h Volume:
1.82M
Relative Volume:
1.52
Market Cap:
$59.78B
Revenue:
$3.21B
Net Income/Loss:
$43.57M
P/E Ratio:
1,896.22
EPS:
0.2405
Net Cash Flow:
$221.36M
1W Performance:
-1.59%
1M Performance:
+0.01%
6M Performance:
+73.24%
1Y Performance:
+71.06%
1-Day Range:
$441.22
$459.77
1-Week Range:
$436.51
$485.36
52-Week Range:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersEarnings Overview Report & Precise Buy Zone Tips - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentum2025 Stock Rankings & Long-Term Safe Investment Plans - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.July 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stockWeekly Investment Report & Safe Entry Point Identification - newser.com
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.Earnings Performance Report & Growth Focused Stock Reports - newser.com
Alnylam Pharmaceuticals Hits Day Low of $436.51 Amid Price Pressure - Markets Mojo
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Yahoo Finance
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
ANTIPODES PARTNERS Ltd Sells 36,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikes2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Strs Ohio Has $9.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Focus Partners Advisor Solutions LLC Has $263,000 Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flows2025 Trading Recap & Growth Oriented Trade Recommendations - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureMarket Growth Review & Free Community Consensus Stock Picks - newser.com
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsJuly 2025 Review & Capital Efficiency Focused Strategies - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2025 Earnings Call Transcript - Insider Monkey
A Fresh Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Q3 Profit Surge and Upgraded Guidance - simplywall.st
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Piper Sandler Reiterates "Overweight" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $527.00 at Barclays - MarketBeat
Evercore ISI Sticks to Their Buy Rating for Alnylam Pharma (ALNY) - The Globe and Mail
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboards2025 Macro Impact & Short-Term High Return Strategies - newser.com
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose - ADVFN
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - ADVFN
Howard Capital Management Inc. Makes New $271,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. continue its uptrendIndex Update & Community Shared Stock Ideas - newser.com
How Alnylam's Raised 2025 Revenue Outlook and AMVUTTRA Uptake Will Impact ALNY Investors - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Profitability Milestone Reinforces Bull Case Ahead of Forecasted 52% Earnings Growth - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down on Analyst Downgrade - MarketBeat
Jefferies Financial Group Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $549.00 - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Earnings Results - MarketBeat
Alnylam Pharmaceuticals: Q3 Earnings ReviewA Sensational Year Reaches Its Peak (ALNY) - Seeking Alpha
Alnylam Pharmaceuticals (ALNY US): On Track for S&P500 Inclusion Following Positive Earnings - Smartkarma
ALNY: Piper Sandler Raises Price Target Amid Overweight Rating | - GuruFocus
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales - sharewise.com
Barclays Raises Price Target for Alnylam Pharmaceuticals (ALNY) to $527 | ALNY Stock News - GuruFocus
Strong Demand for Narrow-Moat Alnylam's Amvuttra Drives Growth; Pipeline Continues to Make Progress - Morningstar
Jennison Associates LLC Has $114.15 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam: Q3 Earnings Snapshot - Stamford Advocate
How to recover losses in Alnylam Pharmaceuticals Inc. stockJuly 2025 Closing Moves & Advanced Swing Trade Entry Alerts - newser.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):